| Q36744836 | Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus |
| Q105340892 | Antibacterial activity of flavanone isolated fromSophora exigua against methicillin-resistantStaphylococcus aureus and its combination with antibiotics |
| Q40326211 | Antibiotic combinations. |
| Q36632795 | Antibiotic combinations: should they be tested? |
| Q37063182 | Antimicrobial resistance of Staphylococcus aureus: genetic basis. |
| Q39828319 | Bactericidal activity and killing rate of serum in volunteers receiving teicoplanin alone or in combination with oral or intravenous rifampin |
| Q40281952 | Bioassay for determination of vancomycin in the presence of rifampin or aminoglycosides |
| Q30451383 | Characteristics of rifampin-resistant variants obtained from clinical isolates of Staphylococcus aureus |
| Q39799150 | Clinical Use of Rifampicin in Combination for Non-Mycobacterial Infections: A Survey of Published Evidence |
| Q43652825 | Clinical and Microbiologic Aspects of Serious Infections Caused by Staphylococcus Epidermidis |
| Q35536476 | Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections |
| Q40145535 | Combination Antimicrobial Therapy |
| Q34107094 | Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus |
| Q35116767 | Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus |
| Q40283322 | Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus |
| Q35647232 | Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections |
| Q39855636 | Effect of mixing on rifampin bactericidal activity against staphylococci |
| Q40283168 | Effect of storage and changes in bacterial growth phase and antibiotic concentrations on antimicrobial tolerance in Staphylococcus aureus |
| Q39746366 | Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus |
| Q39867979 | Efficacy of ticarcillin-clavulanic acid for treatment of experimental Staphylococcus aureus endocarditis in rats |
| Q39842918 | Endocarditis updated |
| Q33726771 | Factors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin |
| Q35740437 | In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus |
| Q42928409 | In vitro activity of teichomycin and vancomycin alone and in combination with rifampin |
| Q40164266 | In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations |
| Q35575038 | In vitro susceptibilities of four species of coagulase-negative staphylococci |
| Q35893075 | Influence of rifampin therapy on serum bactericidal activity in the presence of cloxacillin and vancomycin |
| Q37022592 | Ingestion of Staphylococcus aureus by bovine endothelial cells results in time- and inoculum-dependent damage to endothelial cell monolayers. |
| Q39855356 | Interaction Between Vancomycin and Rifampin Against Staphylococcus aureus |
| Q77925917 | Internal jugular vein haemodialysis catheter-induced right atrium endocarditis--case report and review of the literature |
| Q35376362 | Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. |
| Q36632851 | Methicillin-resistant staphylococci |
| Q35566190 | Methicillin-resistant staphylococci: detection methods and treatment of infections |
| Q37821604 | Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy |
| Q35136634 | Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium |
| Q35138989 | Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. |
| Q45127594 | Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections |
| Q35716241 | Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations |
| Q34783668 | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia |
| Q70220876 | Rifampin |
| Q36915993 | Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials |
| Q42120356 | Rifampin therapy for Staphylococcus epidermidis endocarditis. |
| Q33750776 | Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin |
| Q40453776 | Susceptibility and Synergy Studies of Methicillin-Resistant Staphylococcus epidermidis |
| Q42143331 | Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains |
| Q33756241 | Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus |
| Q40667218 | The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper |
| Q35284471 | Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus |
| Q54521694 | Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis. |
| Q39882511 | Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia |
| Q70243081 | Vancomycin |
| Q54530065 | Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts |
| Q24675979 | Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users |
| Q38462842 | Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice |
| Q50587156 | Vancomycin--new uses for an old drug. |
| Q71457689 | [Staphylococcal endocarditis. New diagnostic and therapeutic trends] |